Dainippon Sumitomo To Launch Diabetes Drug Surepost
This article was originally published in PharmAsia News
Dainippon Sumitomo Pharma will launch rapid-acting insulin Surepost (repaglinide) in Japan May 16. The insulin is the third in its class in Japan, after Fastic (nateglinide) from Ajinomoto/Astellas Pharma Inc., and Glufast (mitiglinide) from Kissei Pharmaceutical. (Click here for more - Japanese language
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.